medigraphic.com
ISSN 1561-3119 (Electronic)

2021, Number 2

<< Back Next >>

Rev Cubana Pediatr 2021; 93 (2)

Relationship between SARS-CoV-2, gut microbiota and the presence of digestive symptoms

Mena MVR

Language: Spanish
References: 27
Page: 1-9
PDF size: 520.74 Kb.


ABSTRACT

Introduction: Gastrointestinal symptoms associated with COVID-19 can affect between 3 and 39% of patients.
Objective: Examine the relationship between infection with the virus, the gut microbiota and the presence of digestive symptoms.
Methods: Bibliographic search in Medline, Pubmed, Scielo, LILACS and Cochrane in the last 6 months of 2020 in English and Spanish languages on the presence of digestive symptoms in COVID-19 patients.
Results: The lung-intestinal axis is bidirectionally connected, so the metabolites and microbes of the lung can affect the gut microbiota and thus justify the possibility that SARS-CoV-2 will have an impact on that ecosystem. SARS-CoV-2 RNA detection has been confirmed in stool samples even after respiratory sample results have been negative, implying that the fecal-oral mechanism is a possible route of transmission of the disease. Gastrointestinal symptoms associated with SARS-CoV-2 infection are: anorexia, nausea, abdominal pain and vomiting, the latter is the most common symptom in the pediatric population. Patients who had diarrhea were associated with an unfavorable evolution of the disease, although the hypotheses raised in this regard are not yet confirmed.
Final considerations: More research is needed on alterations of the gut microbiota, the potential fecal-oral transmission of SARS-CoV-2 and the characterization of digestive manifestations in COVID-19 patients. Biosecurity measures are important for the handling of biological waste of the patients.


REFERENCES

  1. Cañete Villafranca R, Noda Albelo AL, Ferreira Moreno V, Brito Pérez K, García Herrera Arístides L. SARS-Cov-2, el virus emergente que causa la pandemia de COVID-19. Rev Med Electrón. 2020 [acceso 24/11/2020];42(3):1862-81 Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1684-18242020000301862&lng=es

  2. Zuo T, Zhang F, Grace CYL, Yeoh YK, Li AYL. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159(3):944-55.e8. doi: http://doi: 10.1053/j.gastro.2020.05.048

  3. López PGT, Ramírez SMLP, Torres AMS. Participantes de la respuesta inmunológica ante la infección por SARS-CoV-2. Alerg Asma Inmunol Pediatr. 2020;29(1):5-15. doi: http://doi:10.35366/93321

  4. Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, et al. High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut. 2016;651812-21. doi: https://doi.org/10.1136/gutjnl-2015-309957.

  5. Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Cell Microbiol. 2018;20(12):e12966 doi: http:// doi: 10.1111/cmi.1296.6.

  6. He Y, Wen Q, Yao F, Xu D, Huang Y, Wang J. Gut -lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol. 2017;43(1):895. doi: http://doi.org/10.1080/1040841X.2016.1176988

  7. Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, et al. SARSCoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020;69:1143-1144. doi: https://doi.org/10.1136/gutjnl-2020-320891

  8. Yang X, Zhao J, Yan Q, Zhang S, Wang Y, Li Y. A case of COVID-19 patient with the diarrhea as initial symptom and literature review. Clin Res Hepatol Gastroenterol. 2020;44(5):e109-e112. doi: http://doi.org/10.1016/j.clinre.2020.03.013

  9. Azwar MK, Kirana F, Kurniawan A, Handayani S, Setiati S. Gastrointestinal Presentation in COVID-19 in Indonesia: A Case Report. Acta Med Indones. 2020;52(1):63-7.

  10. Fuentes Díaz CF, Zabaleta Taboada OY. Manifestaciones gastrointestinales de la infección por el "nuevo coronavirus". Rev Colomb Gastroenterol. 2020;35(1):69-72. doi: http://doi.org/10.22516/25007440.541

  11. Quintero Marzola ID, Rodríguez Blanco JD, Galindo Velásquez HA, Quintana Pájaro L, Ramos Villegas Y. Evidencia de alteraciones gastrointestinales en COVID-19: Manifestaciones y teorías en fisiopatología. Rev Colomb Gastroenterol. 2020;35(2):248-52. doi: https://doi.org/10.22516/25007440.559

  12. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of S:ARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020;5(4):335-7. doi: http://doi.org/10.1016/S2468-1253(20)30048-0

  13. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;81(2):27180.e8. doi: http://doi.org/10.1016/j.cell.2020.02.052.

  14. Hashimoto T, Perlot T, Rehman A. Trichereau J, Ishiguro H. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012 [acceso 20/11/2020];487:477-81. Disponible en: https://www.nature.com/articles/nature11228

  15. Schmulson M, Dávalos MF, Berumen J. Beware: Gastrointestinal symptoms can be a manifestation of COVID-19. Rev Gastroenterol Mex. 2020;85(3):282-7. doi: htpp//doi:10.1016/j.rgmx.2020.04.001

  16. Lee IC, Huo TI, Huang YH. Gastrointestinal and Liver Manifestations in Patients with COVID-19. J Chin Med Assoc. 2020;83(6):521-3. doi: https://doi.org/10.1097/JCMA.0000000000000319

  17. Liang W, Feng Z, Rao S, Xiao C, Xue X. Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus. Gut. 2020;69:1141-3. doi: http ://doi:10.1136/gutjnl-2020-320832

  18. Xu Y, Li X, Zhu B, Liang H, Fang C. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nature Med. 2020;26(4):502-4. doi: http://doi.org/10.1038/s41591-020-0817-4

  19. Musa S. Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): What do we know till now? Arab J Gastroenterol. 2020;21(1):3-8. doi: https://doi.org/10.1016/j.ajg.2020.03.002.

  20. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19. Abnormal liver funtions test. J Hepatol. 2020;73(3):566-74. doi: htpp://doi.org/10.1016/j.jhep.2020.04.006

  21. Fen G, Zheng KI, Yan QQ, Rios RS, Targher G. Covid 19 and liver disfunction: current insight and emergent therapeutic strategies. J Clin Trans Hepatol. 2020;8(1)18-24. doi: htpp//doi:10.14218/JTCH.2020.00018

  22. Li G, Fan Y, Lai Y, Han T, Li Z. Coronavirus infections and immune responses. J Med Virol. 2020;92(4):424-32. doi: htpp// doi: 10.1002/jmv.25685

  23. Herrera-Lasso Regas V, Lleonart Bellfill R. Reacciones adversas a fármacos utilizadas en el tratamiento específico de la infección por SARS-CoV-2. Med Clin. 2020;155(10):448-53. doi: htpp//doi.org/10.1016/j.medcli.2020.06.019.

  24. Yang JK, Lin SS, Ji XJ, Guo LM. Biding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010;47(3):193-9. doi: htpp://doi 10.1007/00592-009-0109-4

  25. Laviano A, Koverech A, Zanetti M. Nutrition support in the time of SARS-CoV-2 (COVID-19) [editorial]. Nutrition. 2020;74:110834. doi: : htpp://doi.org/10.1016/j.nut.2020.110834

  26. Carabaño Aguado I. SARS-CoV-2 aparato digestivo. Rev Ped Aten Primaria. 2020 [acceso:14/09/2020];22(86):189-94. Disponible en: https://www.pesquisa.bvsalud.org/portal/resource/es/

  27. Tian Y, Rong L, Nian W, He Y. Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):84351. doi: http://doi.org/10.1111/apt.15731




2020     |     www.medigraphic.com